Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.